Cancer Vaccines

With ten million persons afflicted each year, no one is entirely immune to cancer and its devastating effects on individuals and families. But recent advances in the development of cancer vaccines—either as therapeutic agents or as preventative measures—are hopeful indicators of progress in this field. This volume comprises invited chapters from world-renowned researchers and clinicians that shed light on recent steps forward in immunotherapeutic and preventive approaches for future cancer vaccines.

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.

Some Scientific and Organizational Challenges in Cancer Immunology 1

The Human Cancer Antigen Mesothelin is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC-205/CD205 Receptor on Dendritic Cells 6

Brain Tumor Immunotherapy with Type-1 Polarizing Strategies 18

Harnessing Human Dendritic Cell Subsets to Design Novel Vaccines 24

Dendritic Cell-based Vaccines for Pancreatic Cancer and Melanoma 33

Combining Conventional Therapies with Intratumoral Injection of Autologous Dendritic Cells and Activated T Cells to Treat Patients with Advanced Cancers 41

Witch Hunt Against Tumor Cells Enhanced by Dendritic Cells 51

Harnessing CD1D-restricted T Cells Toward Antitumor Immunity in Humans 61

Immunity Against Cyclin B1 Tumor Antigen Delays Development of Spontaneous Cyclin B1-Positive Tumors in P53-/- Mice 68 Targets of Protective Tumor Immunity 74

Identification of Immunologic Biomarkers Associated with Clinical Response After Immune-based Therapy for Cancer Harnessing Dendritic Cells to Generate Cancer Vaccines 81

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells 99

Strategies to Enhance the Therapeutic Activity of Cancer Vaccines: Using Melanoma as a Model 107

Hematopoietic Stem and Progenitor Cells and the Inflammatory Response 118

Ralph Marvin Steinman was a Canadian physician and medical researcher at Rockefeller University, who in 1973 discovered and named dendritic cells while working as a postdoctoral fellow in the laboratory of Zanvil A. Cohn, also at Rockefeller University. Kenichiro Hasumi is the editor of Cancer Vaccines: Sixth International Symposium, Volume 1174, published by Wiley.